

**ViiV Healthcare-sponsored or supported studies to be presented at CROI 2025:**

Title	Presenting author	Presentation
<b>Cabotegravir for Pre-exposure prophylaxis (PrEP)</b>		
PILLAR month 12 clinical results: zero HIV acquisition and high persistence with CAB LA for PrEP	T. Khan	Oral Abstract 196 12 March 2025 10:00 AM PT
Performance of HIV RNA screening in the context of long-acting injectable cabotegravir in HPTN 084	S. Delany-Moretlwe	Oral Abstract 195 12 March 2025 10:00 AM PT
ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations	B. Grinsztejn	Oral Abstract 192 12 March 2025 10:00 AM PT
Estimation of prevention-effective CAB-LA concentrations among MSM/TGW in HPTN 083	B. Hanscom	Oral Abstract 193 12 March 2025 10:00 AM PT
Response to HIV Treatment After Long-Acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083	R. Landovitz	Oral Abstract 197 12 March 2025 10:00 AM PT
No increased risk for hypertension with CAB-LA compared to TDF/FTC for PrEP: results from HPTN 084	S. Delany-Moretlwe	Poster 820

High incidence of curable sexually transmitted infections in HPTN 084: a tertiary analysis	H. Nuwagaba-Biribonwoha	Poster 1226
PrEP choices among sexual and gender minorities in Brazil: the ImPrEP CAB-LA study	B. Grinsztejn	Poster 1356
Depression and suicide risk among sexual and gender minorities: insights from the ImPrEP CAB Brazil	D. Richer Araujo Coelho	Poster 1302
Patterns of first choice, switching, and discontinuation of oral and injectable PrEP among adolescents from sexual and gender minorities in Brazil	L. Magno Santos de Sousa	Poster 1203
Acceptability of long-acting cabotegravir among pregnant and lactating people in South Africa	N. Wara	Poster 1357
Impact of rapid long-acting prep scale-up among MSM: closing the unmet needs and towards ending HIV	H. Wang	Poster 1297
Expanding the PrEP method market: Early insights from offering oral PrEP, PrEP ring, and injectable CAB PrEP for HIV prevention across five countries in Africa	N. Naidoo	Poster 1354
Dynamic choice HIV prevention in the context of injectable cabotegravir (CAB-LA): a model-based cost-effectiveness analysis	M. Hickey	Poster 1293
Use of DNA profiling to resolve discrepant HIV tests in the setting of injectable cabotegravir PrEP	J. Fogel	Poster 1193

## **Cabotegravir for Treatment**

Randomized trial of cabotegravir and rilpivirine long-acting in Africa (CARES): week 96 results	C. Kityo	Oral Abstract 202 12 March 2025 12:15 PM PT
Long-term CAB+RPV LA effectiveness in virologically suppressed individuals in the OPERA cohort	M. Sension	Poster 674
Clinical outcomes among virologically suppressed women receiving CAB+RPV LA in the OPERA cohort	J. Altamirano	Poster 676
Outcomes on cabotegravir + rilpivirine in suppressed people with HIV (PWH) in TRIO health US cohort	P. Sax	Poster 675
Decreasing oral induction duration in support of LAI ART use with hard-to-reach populations	A. Rana	Poster 692
At home CAB/RPV provides novel approach to achieve viral suppression in adherence challenged PWH	M. Dieterich	Poster 1318
Safety and pharmacokinetics of long-acting cabotegravir and rilpivirine in children between 20-40kgs	M. Archary	Poster 1046
Interim Week 48 results in South African youth living with HIV on long-acting injectable therapy: AFINAty study	L. Jennings	Poster 679
<b>Pipeline</b>		
Proof-of-concept trial of VH4524184 (VH-184), a third-generation integrase strand transfer inhibitor	L. Rogg	Oral Abstract 152 11 March 2025

		10:13-10:21 PT
Proof-of-concept trial of oral VH4011499 (VH-499), a new HIV-1 capsid inhibitor	P.I Benn	Oral Abstract 153 11 March 2025 10:21-10:30 PT
VH3810109 (N6LS) efficacy and safety in adults who are virologically suppressed: The EMBRACE study	B. Taiwo	Oral Abstract 203 12 March 2025 12:39-12:46 PT
Pre-clinical evaluation of effector function-enhanced variants of N6 bnAb	D. Wensel	Poster 547
<b>Fostemsavir</b>		
Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs)	H. Qi	Poster 507
Characteristics and treatment outcomes of people with HIV prescribed fostemsavir in the trio cohort	M. Ramgopal	Poster 699
<b>Dolutegravir</b>		
Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH	R. Ryan	Oral Abstract 119 10 March 2025 12:39-12:46 PT

PK and safety of chronic dolutegravir administration in neonates exposed to HIV-1 (IMPAACT 2023)	J. Momper	Poster 1047
Baseline and emergent resistance profiles in the African paediatric CHAPAS-4 trial	A. Bamford	Poster 123
Drug interactions between dolutegravir (DTG) and escalating doses of rifampicin (RIF): DORIS study	Y. Singh	Poster 645
Switching to DTG/3TC vs. BIC/FTC/TAF and steatotic liver disease: A sub-study of PASODOBLE Trial	J. Pineda	Poster 764
Depression, sleep, and anxiety among pregnant and postpartum women using dolutegravir and efavirenz	D. Wu	Poster 986
Changes in body composition in people with HIV switching to DTG/3TC or BIC/TAF/FTC	E. Martinez	Poster 897
Effectiveness and inflammatory markers after 144 weeks of switch to DTG/3TC in a randomized trial	E. Blomme	Poster 663
Switch to DTG/3TC vs BIC/FTC/TAF (PASO-DOBLE study): Efficacy and Weight Changes by Predefined Subgroups	J. Tiraboschi	Poster 661
Impact of art simplification with dolutegravir and lamivudine on the HIV reservoir	Fombellida-Lopez	Poster 664
Risk of obesity, cardiometabolic disease and MACE after switch to an integrase inhibitor in REPRIEVE	E. Kileel	Poster 838

Risk of incident hypertension with common antiretroviral agent combinations in the OPERA cohort	G. Pierone Jr	Poster 823
<b>General HIV</b>		
Brain volume normalization after 96 weeks of ART started during acute HIV infection	R. Paul	Oral Abstract 167 12 March 2025 10:00 AM PT
People with HIV exhibit structural brain changes following infection with SARS-Cov-2	J. Bolzenius	Oral Abstract 174 12 March 2025 10:00 AM PT
Frailty is associated with higher MACE incidence but does not appear to modify pitavastatin effects	K. Erlandson	Oral Abstract 179 12 March 2025 10:00 AM PT
Plaque, inflammation, subclinical myocardial injury and MACE in the REPRIEVE mechanistic substudy	S. Grinspoon	Oral Abstract 178 12 March 2025 10:00 AM PT
Cancer incidence in women with HIV in Europe and Australia: a combined D:A:D and RESPOND cohort analysis	W. M. Han	Poster 803
Statin effect heterogeneity on plaque volume & composition in the REPRIEVE mechanistic substudy	B. Foldyna	Poster 850

No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV	K. Erlandson	Poster 624
Prognostic factors of physical function decline in the PREPARE study	G. Ditzenberger	Poster 881
Time-updated win ratio aligns with primary REPRIEVE findings and suggests early pitavastatin benefit	E. Smith	Poster 853
Determinants of steatotic liver disease among people with HIV in Europe and Australia	C. Riebensahm	Poster 762
Hospitalization incidence among young children living with HIV in the Western Cape, South Africa	K. Anderson	Poster 1051
People with HIV at high cardiovascular risk were undertreated with statins	S. Esser	Poster 851
Increasing methamphetamine use and group sex observed in MSM with acute HIV infection in Bangkok	P. Chan	Poster 1144
Heart failure risk and events in people with HIV in the REPRIEVE trial	M. Watanabe	Poster 818
Cognitive trajectories 1 year before and after COVID-19 in an AHI cohort	F. Ocampo	Poster 926
Immune and virologic trajectories 1.5 years before and after COVID-19 in an early-treated HIV cohort	F. Ocampo	Poster 931

ART exposure and accelerated aging in PLHIV: insights from proteomic and methylation clocks	N. Vadaq	Poster 866
CCR5 Expression Is Critical for the Maintenance of HIV Control and Reservoir Size	J. dos Santos	Poster 563
Genetic regulation of immune responses to CMV in spontaneous HIV controllers	S. Ruijten	Poster 499
Delayed HIV-1 rebound correlates with enhanced CD8 T Cell activation in human trials	R. Thomas	Poster 484
Rapid clearance of the inducible HIV-1 reservoir after initiation of antiretroviral therapy	M. Puertas	Poster 571
Virulent HIV-1B: clinical challenges and proteomic insights	K. Mehta	Poster 358
Distinct metabolic perturbations link liver steatosis and incident CVD in lean but not obese PLHIV	N. Vadaq	Poster 760
Mitochondrial gene variants in VARS2 influence HIV reservoir and T cells in European HIV controllers	V. Rios Vazquez	Poster 487
Multiomics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort	V. Rios Vazquez	Poster 565
Heterogeneity of PD-1 Expression in PLHIV and Its Relationship With Host and Viral-Related Factors	A. Navas	Poster 462



Residual HIV Viremia Associates With Reservoir Size, but Not With Immune Activation or Inflammation	T. Otten	Poster 355
Neuronal injury in a subset of individuals during acute HIV infection and after immediate treatment	P. Chan	Poster 615
Early HIV-1 genetic diversity includes CTL and drug resistance mutations	J. Coffin	Poster 346
RV550: the effects of IL-15 super-agonist N-803 with ART in acute infection on T and NK cells	H. Takata	Poster 444
RV550: Safety and virological outcomes in blood and lymph nodes of N-803 with ART in acute infection	C. Sacdalan	Poster 512
Sex-based differences and genetic regulation of cytokine responses in people living with HIV	S. Ruijten	Poster 371
Females with HIV favor interferon responses over inflammation upon TLR7 activation	A. Huber	Poster 470
<b>Translational bNAbs</b>		
Maximizing benefits to participants in analytic treatment interruption studies with bnAb infusions	Y. Li	Poster 508
Sensitivity of HIV-1 CRF01_AE Envelopes to Broadly Neutralizing Antibodies VRC07-523 and PGDM1400	G. Smith	Poster 421